Blueprint Medicines Balance Sheet Health
Financial Health criteria checks 4/6
Blueprint Medicines has a total shareholder equity of $130.6M and total debt of $680.4M, which brings its debt-to-equity ratio to 521%. Its total assets and total liabilities are $1.0B and $918.6M respectively.
Key information
521.0%
Debt to equity ratio
US$680.44m
Debt
Interest coverage ratio | n/a |
Cash | US$710.64m |
Equity | US$130.61m |
Total liabilities | US$918.64m |
Total assets | US$1.05b |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: 2L9's short term assets ($808.4M) exceed its short term liabilities ($214.9M).
Long Term Liabilities: 2L9's short term assets ($808.4M) exceed its long term liabilities ($703.7M).
Debt to Equity History and Analysis
Debt Level: 2L9 has more cash than its total debt.
Reducing Debt: 2L9's debt to equity ratio has increased from 0% to 521% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: 2L9 has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if 2L9 has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.